Recently, Shanghai WD Pharmaceutica$ ∏÷l Co., Ltd. (hereinafter referred¶© to as WD Pharma) and Boehringer I←→Ωngelheim China (hereinafter referre> d to as Boehringer Ingelheim) j←♣♦↑ointly announced that Boehring→™©er Ingelheim will leverage WD Pha↑∑₽rma's AcuSiS® te&↓chnology platform to explore innoδ§∞vative drug delivery techniques to ​‌Ωaddress the clinical dosing ♦&'challenges faced by ε€pediatric and geriatric patients♣", thereby improving med₩€ication compliance.

The development of fσ≠ormulations for pedi∞™♣atric and geriatric patients  §‍has long been hampered b↕≈α₹y issues such as swallowing dif ​♣ficulties and palatability γ₹∏concerns, resulting i±≠n a lack of specialized <♥formulations. Existing dosage f÷♠'orms can only partially address sw®÷εallowing issues but often introduc≠∑e palatability issues. WD Pharma&×≠♣∑#39;s proprietary universal teλπγchnology platform, AcuSiS®,​λ↓ can accommodate varββious dosage forms such as granules, pe☆←llets, and microtablets, prov★Ω☆iding high flexibility. This novel s©©≠×olid oral dosage form simultaδ§neously addresses both swallo♠π↓wing and palatability is€©$πsues, requires no preparation, is ∑δ↑easy to use, and offers discreeφ<t dosing that can alleviate ↓↕♠patients' fear of medication and‌★π improve medication compli‍♦​ance.

Dr. Liang C. Dong, CEO of WD Pharma, st​₩ated, "WD Pharma is honored toσ≥ enter into this colla₹≤boration with Boehringer IΩ× βngelheim. Since its inception, WD π ΩΩPharma has been deeply committe₽‍<d to the development of ↑$≈innovative drug delivery systemsε± and is dedicated to idenφ®tifying and addressing unmet cl±§♣>inical needs to provide patients with ₩∞​×the latest medical technologi±₽Ω£es and the best treatment experienc≤★↓e. AcuSiS®, as a novel oral drug dφ elivery device capable of simulε÷≤♥taneously addresses swallowing an<₽₽×d palatability issues and a¶π★chieve the goal of 'med<★✔¥icine without bitterness and do₽$←↔sing without hands,'♠®φ₩; while reducing resear'δ÷ch and development pressures and ac₩♦celerating clinical trials. ₽ ¥®Through this collaboration with Boe€π‌hringer Ingelheim, we hope to fin•∏®d a  fast and efficient way &φto develop pediatric and geriatric€≥♠ products".

Dr. Zhang Wei, Senior V→₩​φice President of Research and¶♣♦ Development and Medic∑±al Affairs for Boehringer ‌∞αIngelheim Greater China, commented, ≈↑π"Boehringer Ingelheim has al∑​ways adhered to a patient-centric innov✘ ¥ation strategy in research and developδ☆∞×ment. We not only focus <→®≥on the discovery and clinical researc₽₽✔h of innovative drug •γ€s, but also pay close attention to the ∏λ★needs of different pat₹®ient groups in terms of drug delivery↑≈∞↕ methods. Through this collaboratio≠Ωn with WD Pharma, we hope to≥​σ← innovate in the area '∞★&of drug delivery and br←εing innovative dosing meth↔$Ωσods to patients with swa↔♣llowing difficulties. Furthermore, w✔•‍✘e aim to apply this technology to B$×oehringer Ingelheim's gloε•bal drug development efforts, fulfi™σlling our commitment to γ×✘ε“developing innovation in C±¶♦←hina for the global community&qu←✔πot;.

About WD Pharma:

Shanghai WD Pharmaceutical Co., Ltd. w& as established in January 2016 in Sh§€♦ anghai Zhangjiang Hi-Tech Par∏α₽k. The company specializes in develo £<©ping innovative drug delivery techno÷←€logy platforms that integrate acti♠β✘₹ve pharmaceutical ingredients  ∞and medical devices. It★∏δ is committed to developing →♠∏novel products with global i απ↔ntellectual property rights ✔©and significant clinical advantages.↑≤§ WD Pharma has developed s​‌®everal technology pl≠✔atforms and a diversified produc$εt pipeline. Currently, th±Ω≥e company has develoσ→ ☆ped proprietary drug/dev€±™γice combination delivery systems₩×±". Four clinical-stage σ∞products cover the ful€©↓l spectrum of Parkinson'☆ ↔♠;s disease treatment←$α.

About Boehringer Ingelheim•β Greater China:

Headquartered in Ingelheim,♦¶ Germany, Boehringer Ingelheim is one Ω∏of the world's leadingα÷λ biopharmaceutical companies™​, with more than 53,000 employees wor₩ ldwide. Our core business is ←£λ™to develop new and better drugs foε ↑σr humans and animals. Boe ©hringer Ingelheim Greater Chi€'↑na is headquartered in Sha€•σnghai and currently employs more than >' 3,800 people across the country. Its c↓★ore businesses include humπ™ an pharmaceuticals, an∑‌"↑imal health, and biopharmaceu'<εtical contract manufacturing$∑™₩. In recent years, Boehri♥ nger Ingelheim has achieve↕"γ≤d significant growth in China an✔βd has been recognized as a "§♣Top Employer in China" for ten co®​≥$nsecutive years. China is one o&‌δf Boehringer Ingelheim's key market©λ♠®s and innovation hubs. The compa♥πny integrates the needs of Chinese pa €™Ωtients into its global $©research and developme£↑¥‍nt strategy, strivin↓↔♥g to bring more innovative products ‌δ≤to Chinese patients sooner, co♠←'ntribute to the high-qu§"ality development of China's heal♠₽×£thcare industry, and c ↑ ↑omprehensively improve the he↓©♣alth of humans and animals.&nφ>bsp;